BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 26494964)

  • 1. Genetic background in nonalcoholic fatty liver disease: A comprehensive review.
    Macaluso FS; Maida M; Petta S
    World J Gastroenterol; 2015 Oct; 21(39):11088-111. PubMed ID: 26494964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis.
    Dongiovanni P; Romeo S; Valenti L
    Biomed Res Int; 2015; 2015():460190. PubMed ID: 26273621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic backgrounds in nonalcoholic fatty liver disease.
    Seko Y; Yamaguchi K; Itoh Y
    Clin J Gastroenterol; 2018 Apr; 11(2):97-102. PubMed ID: 29492830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNPLA3 I148M variant in nonalcoholic fatty liver disease: demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis.
    Chen LZ; Xin YN; Geng N; Jiang M; Zhang DD; Xuan SY
    World J Gastroenterol; 2015 Jan; 21(3):794-802. PubMed ID: 25624712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.
    Anstee QM; Seth D; Day CP
    Gastroenterology; 2016 Jun; 150(8):1728-1744.e7. PubMed ID: 26873399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity.
    Sookoian S; Castaño GO; Scian R; Mallardi P; Fernández Gianotti T; Burgueño AL; San Martino J; Pirola CJ
    Hepatology; 2015 Feb; 61(2):515-25. PubMed ID: 25302781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
    Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
    Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease.
    Targher G; Byrne CD
    Metab Syndr Relat Disord; 2015 Aug; 13(6):235-8. PubMed ID: 25714786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.
    Zhou Y; Llauradó G; Orešič M; Hyötyläinen T; Orho-Melander M; Yki-Järvinen H
    J Hepatol; 2015 Mar; 62(3):657-63. PubMed ID: 25457209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome.
    Wainwright P; Byrne CD
    Int J Mol Sci; 2016 Mar; 17(3):367. PubMed ID: 26978356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation.
    Tilg H; Moschen A
    Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):391-6. PubMed ID: 20473151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics of nonalcoholic fatty liver disease.
    Dongiovanni P; Valenti L
    Metabolism; 2016 Aug; 65(8):1026-37. PubMed ID: 26409295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.
    Dongiovanni P; Anstee QM; Valenti L
    Curr Pharm Des; 2013; 19(29):5219-38. PubMed ID: 23394097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.
    Li YY
    World J Gastroenterol; 2012 Dec; 18(45):6546-51. PubMed ID: 23236228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease.
    Brady GF; Kwan R; Ulintz PJ; Nguyen P; Bassirian S; Basrur V; Nesvizhskii AI; Loomba R; Omary MB
    Hepatology; 2018 May; 67(5):1710-1725. PubMed ID: 28902428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
    Park JH; Cho B; Kwon H; Prilutsky D; Yun JM; Choi HC; Hwang KB; Lee IH; Kim JI; Kong SW
    Liver Int; 2015 Dec; 35(12):2537-46. PubMed ID: 26148225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.